Markets:

Overview

News

Currencies

International

Treasuries

Veracyte, Inc. - Common Stock (NQ:VCYT)

46.71 -13.07 (-21.86%)

Streaming Delayed Price Updated: 3:30 PM EDT, Jul 31, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Veracyte, Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Veracyte to Participate in 11th Annual SVB Leerink Global Healthcare Conference

February 08, 2022

From Veracyte, Inc.

Via Business Wire

Veracyte Announces New Data to be Presented at the 2022 ASCO Genitourinary (GU) Cancers Symposium

January 31, 2022

From Veracyte, Inc.

Via Business Wire

New Data Suggest Veracyte’s Percepta Genomic Sequencing Classifier Can Help Accelerate Timely Treatment for Patients with Early-Stage Lung Cancer

January 24, 2022

From Veracyte, Inc.

Via Business Wire

Stocks That Hit 52-Week Lows On Friday ↗

January 14, 2022

During Friday's session, 445 companies made new 52-week lows. Noteable 52-Week Lows: Intuitive Surgical (NASDAQ:ISRG) is the largest company in terms of market cap to...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For January 7, 2022 ↗

January 07, 2022

Upgrades According to Wolfe Research, the prior rating for CVR Energy Inc (NYSE:

Via Benzinga

Veracyte Announces Key Leadership Promotions to Advance Its Strategic Global Vision

January 06, 2022

From Veracyte, Inc.

Via Business Wire

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

December 23, 2021

Gainers Pasithea Therapeutics (NASDAQ:

Via Benzinga

Biotech Playbook 2021 Part 2: Rotation Rally Brings Relief after FED Pivot ↗

December 22, 2021

The new aggressive Fed taper combined with a rise in interest rates for 2022 adds a new element of risk to portfolio management. Monetary policy is a headwind for 2022.

Via Talk Markets

63 Biggest Movers From Friday ↗

December 20, 2021

Gainers Spruce Biosciences, Inc. (NASDAQ: SPRB) jumped 102.8% to close at $5.03 on Friday after Oppenheimer initiated coverage on the stock with an Outperform rating and a $15...

Via Benzinga

Veracyte Announces Publication of Data Demonstrating Clinical Utility of Its Envisia Genomic Classifier to Improve IPF Diagnosis

December 14, 2021

From Veracyte, Inc.

Via Business Wire

Biotech Playbook 2021: No Help From Small Caps In Q4 ↗

December 14, 2021

Mid-cap stock picks have done better today but are way off their 2021 highs. Cryoport and Veracyte are still up and look better technically. Quidel was up 5.48% today on Omicron concerns globally but...

Via Talk Markets

Rising Cases of Early-Onset Colorectal Cancer Calls for Expanded Biotech Screening Methods

December 01, 2021

FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – December 1, 2021 – Early onset colorectal cancer is currently on the rise [[1]], according to a new study [[2]] from the...

Via FinancialNewsMedia

Veracyte Announces Further European Reimbursement Expansion for Prosigna Breast Cancer Test

November 24, 2021

From Veracyte, Inc.

Via Business Wire

Looking for Growth in Small and Mid Cap Life Science Stocks ↗

November 15, 2021

2021 is an unusual year for biotech with a “blow-off” February high in speculative small caps.

Via Talk Markets

Veracyte Announces New Data on Immuno-Oncology Offerings Presented at SITC 2021

November 13, 2021

From Veracyte, Inc.

Via Business Wire

Veracyte Announces Third Quarter 2021 Financial Results

November 09, 2021

From Veracyte, Inc.

Via Business Wire

Earnings Scheduled For November 9, 2021 ↗

November 09, 2021

Companies Reporting Before The Bell • Imara (NASDAQ:IMRA) is projected to report earnings for its third quarter. • KT (NYSE:KT) is projected to report earnings...

Via Benzinga

The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data ↗

November 09, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces...

Via Benzinga

Veracyte Announces Immunoscore Colon Cancer Test Included in ESMO Clinical Practice Guidelines Adapted for Pan-Asia

November 05, 2021

From Veracyte, Inc.

Via Business Wire

New Publication Reinforces Clinical Utility of Afirma Genomic Sequencing Classifier in Thyroid Cancer Diagnosis

November 03, 2021

From Veracyte, Inc.

Via Business Wire

Veracyte Announces New Data To Be Presented at SITC 2021 Will Highlight Company’s Immuno-Oncology Capabilities

November 02, 2021

From Veracyte, Inc.

Via Business Wire

New Data Demonstrate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier in Tailoring Treatment for Prostate Cancer Patients Experiencing Progression After Surgery

October 26, 2021

From Veracyte, Inc.

Via Business Wire

Data Presented at ASTRO 2021 Validate Prognostic Value of Decipher Prostate Genomic Test in Newly Diagnosed, Clinically High-Risk Prostate Cancer

October 25, 2021

From Veracyte, Inc.

Via Business Wire

New Data to be Presented at ASTRO 2021 Further Validate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier

October 14, 2021

From Veracyte, Inc.

Via Business Wire

New Publication Demonstrates Ability of Veracyte’s Decipher Bladder Test to Identify Tumors Most Likely to Respond to Chemotherapy

October 13, 2021

From Veracyte, Inc.

Via Business Wire

Veracyte to Release Third Quarter 2021 Financial Results on November 9, 2021

October 12, 2021

From Veracyte, Inc.

Via Business Wire

New Clinical Utility Data Confirm Veracyte’s Envisia Genomic Classifier Increases Accuracy and Confidence in IPF Diagnosis

October 11, 2021

From Veracyte, Inc.

Via Business Wire

Veracyte Announces New Expanded Data at CHEST Underscoring Percepta Nasal Swab Test’s Ability to Improve Early Lung Cancer Assessment

October 11, 2021

From Veracyte, Inc.

Via Business Wire

New Data to be Presented at CHEST 2021 Showcase Clinical Performance of Veracyte’s Genomic Diagnostic Tests in Lung Cancer and Interstitial Lung Disease

October 06, 2021

From Veracyte, Inc.

Via Business Wire

Is Veracyte Still a Buy After Its Recent Rally? ↗

October 05, 2021

Shares of the genetic diagnostics company are down nearly 50% from their 52-week high in February.

Via The Motley Fool

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.